Introduction of a bioengineered stent with the immobilised antibody against CD34 antigen bound to the surface of the struts represents significant progress in the prevention of thrombotic events. The surface of the BMS is primed to obtain biocompatible matrix and the murine monoclonal antibody against human epitopes of CD34 are attached by covalent binding.